IBDEI0EK ; ; 12-MAY-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;MAY 12, 2016
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,14562,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14562,1,3,0)
 ;;=3^Enlarged Lymph Nodes,Unspec
 ;;^UTILITY(U,$J,358.3,14562,1,4,0)
 ;;=4^R59.9
 ;;^UTILITY(U,$J,358.3,14562,2)
 ;;=^5019531
 ;;^UTILITY(U,$J,358.3,14563,0)
 ;;=D47.3^^61^740^63
 ;;^UTILITY(U,$J,358.3,14563,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14563,1,3,0)
 ;;=3^Essential Thrombocythemia
 ;;^UTILITY(U,$J,358.3,14563,1,4,0)
 ;;=4^D47.3
 ;;^UTILITY(U,$J,358.3,14563,2)
 ;;=^5002258
 ;;^UTILITY(U,$J,358.3,14564,0)
 ;;=C82.09^^61^740^64
 ;;^UTILITY(U,$J,358.3,14564,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14564,1,3,0)
 ;;=3^Follicular Lymphoma Grade I,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,14564,1,4,0)
 ;;=4^C82.09
 ;;^UTILITY(U,$J,358.3,14564,2)
 ;;=^5001470
 ;;^UTILITY(U,$J,358.3,14565,0)
 ;;=C82.00^^61^740^65
 ;;^UTILITY(U,$J,358.3,14565,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14565,1,3,0)
 ;;=3^Follicular Lymphoma Grade I,Unspec Site
 ;;^UTILITY(U,$J,358.3,14565,1,4,0)
 ;;=4^C82.00
 ;;^UTILITY(U,$J,358.3,14565,2)
 ;;=^5001461
 ;;^UTILITY(U,$J,358.3,14566,0)
 ;;=C82.19^^61^740^66
 ;;^UTILITY(U,$J,358.3,14566,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14566,1,3,0)
 ;;=3^Follicular Lymphoma Grade II,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,14566,1,4,0)
 ;;=4^C82.19
 ;;^UTILITY(U,$J,358.3,14566,2)
 ;;=^5001480
 ;;^UTILITY(U,$J,358.3,14567,0)
 ;;=C82.10^^61^740^67
 ;;^UTILITY(U,$J,358.3,14567,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14567,1,3,0)
 ;;=3^Follicular Lymphoma Grade II,Unspec Site
 ;;^UTILITY(U,$J,358.3,14567,1,4,0)
 ;;=4^C82.10
 ;;^UTILITY(U,$J,358.3,14567,2)
 ;;=^5001471
 ;;^UTILITY(U,$J,358.3,14568,0)
 ;;=C82.29^^61^740^68
 ;;^UTILITY(U,$J,358.3,14568,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14568,1,3,0)
 ;;=3^Follicular Lymphoma Grade III,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,14568,1,4,0)
 ;;=4^C82.29
 ;;^UTILITY(U,$J,358.3,14568,2)
 ;;=^5001490
 ;;^UTILITY(U,$J,358.3,14569,0)
 ;;=C82.20^^61^740^69
 ;;^UTILITY(U,$J,358.3,14569,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14569,1,3,0)
 ;;=3^Follicular Lymphoma Grade III,Unspec Site
 ;;^UTILITY(U,$J,358.3,14569,1,4,0)
 ;;=4^C82.20
 ;;^UTILITY(U,$J,358.3,14569,2)
 ;;=^5001481
 ;;^UTILITY(U,$J,358.3,14570,0)
 ;;=C82.39^^61^740^70
 ;;^UTILITY(U,$J,358.3,14570,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14570,1,3,0)
 ;;=3^Follicular Lymphoma Grade IIIa,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,14570,1,4,0)
 ;;=4^C82.39
 ;;^UTILITY(U,$J,358.3,14570,2)
 ;;=^5001500
 ;;^UTILITY(U,$J,358.3,14571,0)
 ;;=C82.30^^61^740^71
 ;;^UTILITY(U,$J,358.3,14571,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14571,1,3,0)
 ;;=3^Follicular Lymphoma Grade IIIa,Unspec Site
 ;;^UTILITY(U,$J,358.3,14571,1,4,0)
 ;;=4^C82.30
 ;;^UTILITY(U,$J,358.3,14571,2)
 ;;=^5001491
 ;;^UTILITY(U,$J,358.3,14572,0)
 ;;=C82.49^^61^740^72
 ;;^UTILITY(U,$J,358.3,14572,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14572,1,3,0)
 ;;=3^Follicular Lymphoma Grade IIIb,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,14572,1,4,0)
 ;;=4^C82.49
 ;;^UTILITY(U,$J,358.3,14572,2)
 ;;=^5001510
 ;;^UTILITY(U,$J,358.3,14573,0)
 ;;=C82.40^^61^740^73
 ;;^UTILITY(U,$J,358.3,14573,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14573,1,3,0)
 ;;=3^Follicular Lymphoma Grade IIIb,Unspec Site
 ;;^UTILITY(U,$J,358.3,14573,1,4,0)
 ;;=4^C82.40
 ;;^UTILITY(U,$J,358.3,14573,2)
 ;;=^5001501
 ;;^UTILITY(U,$J,358.3,14574,0)
 ;;=C82.99^^61^740^74
 ;;^UTILITY(U,$J,358.3,14574,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14574,1,3,0)
 ;;=3^Follicular Lymphoma Unspec,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,14574,1,4,0)
 ;;=4^C82.99
 ;;^UTILITY(U,$J,358.3,14574,2)
 ;;=^5001550
 ;;^UTILITY(U,$J,358.3,14575,0)
 ;;=C82.90^^61^740^75
 ;;^UTILITY(U,$J,358.3,14575,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14575,1,3,0)
 ;;=3^Follicular Lymphoma Unspec,Unspec Site
 ;;^UTILITY(U,$J,358.3,14575,1,4,0)
 ;;=4^C82.90
 ;;^UTILITY(U,$J,358.3,14575,2)
 ;;=^5001541
 ;;^UTILITY(U,$J,358.3,14576,0)
 ;;=R59.1^^61^740^60
 ;;^UTILITY(U,$J,358.3,14576,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14576,1,3,0)
 ;;=3^Enlarged Lymph Nodes,Generalized
 ;;^UTILITY(U,$J,358.3,14576,1,4,0)
 ;;=4^R59.1
 ;;^UTILITY(U,$J,358.3,14576,2)
 ;;=^5019530
 ;;^UTILITY(U,$J,358.3,14577,0)
 ;;=C91.40^^61^740^79
 ;;^UTILITY(U,$J,358.3,14577,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14577,1,3,0)
 ;;=3^Hairy Cell Leukemia,Not in Remission
 ;;^UTILITY(U,$J,358.3,14577,1,4,0)
 ;;=4^C91.40
 ;;^UTILITY(U,$J,358.3,14577,2)
 ;;=^5001771
 ;;^UTILITY(U,$J,358.3,14578,0)
 ;;=C91.42^^61^740^77
 ;;^UTILITY(U,$J,358.3,14578,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14578,1,3,0)
 ;;=3^Hairy Cell Leukemia,In Relapse
 ;;^UTILITY(U,$J,358.3,14578,1,4,0)
 ;;=4^C91.42
 ;;^UTILITY(U,$J,358.3,14578,2)
 ;;=^5001773
 ;;^UTILITY(U,$J,358.3,14579,0)
 ;;=C91.41^^61^740^78
 ;;^UTILITY(U,$J,358.3,14579,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14579,1,3,0)
 ;;=3^Hairy Cell Leukemia,In Remission
 ;;^UTILITY(U,$J,358.3,14579,1,4,0)
 ;;=4^C91.41
 ;;^UTILITY(U,$J,358.3,14579,2)
 ;;=^5001772
 ;;^UTILITY(U,$J,358.3,14580,0)
 ;;=D57.01^^61^740^80
 ;;^UTILITY(U,$J,358.3,14580,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14580,1,3,0)
 ;;=3^Hb-SS Disease w/ Acute Chest Syndrome
 ;;^UTILITY(U,$J,358.3,14580,1,4,0)
 ;;=4^D57.01
 ;;^UTILITY(U,$J,358.3,14580,2)
 ;;=^5002307
 ;;^UTILITY(U,$J,358.3,14581,0)
 ;;=D57.00^^61^740^81
 ;;^UTILITY(U,$J,358.3,14581,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14581,1,3,0)
 ;;=3^Hb-SS Disease w/ Crisis,Unspec
 ;;^UTILITY(U,$J,358.3,14581,1,4,0)
 ;;=4^D57.00
 ;;^UTILITY(U,$J,358.3,14581,2)
 ;;=^5002306
 ;;^UTILITY(U,$J,358.3,14582,0)
 ;;=D57.02^^61^740^82
 ;;^UTILITY(U,$J,358.3,14582,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14582,1,3,0)
 ;;=3^Hb-SS Disease w/ Splenic Sequestration
 ;;^UTILITY(U,$J,358.3,14582,1,4,0)
 ;;=4^D57.02
 ;;^UTILITY(U,$J,358.3,14582,2)
 ;;=^5002308
 ;;^UTILITY(U,$J,358.3,14583,0)
 ;;=D68.32^^61^740^84
 ;;^UTILITY(U,$J,358.3,14583,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14583,1,3,0)
 ;;=3^Hemorrhagic Disorder d/t Extrinsic Circulating Anticoagulants
 ;;^UTILITY(U,$J,358.3,14583,1,4,0)
 ;;=4^D68.32
 ;;^UTILITY(U,$J,358.3,14583,2)
 ;;=^5002357
 ;;^UTILITY(U,$J,358.3,14584,0)
 ;;=C22.2^^61^740^85
 ;;^UTILITY(U,$J,358.3,14584,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14584,1,3,0)
 ;;=3^Hepatoblastoma
 ;;^UTILITY(U,$J,358.3,14584,1,4,0)
 ;;=4^C22.2
 ;;^UTILITY(U,$J,358.3,14584,2)
 ;;=^5000935
 ;;^UTILITY(U,$J,358.3,14585,0)
 ;;=D58.9^^61^740^87
 ;;^UTILITY(U,$J,358.3,14585,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14585,1,3,0)
 ;;=3^Hereditary Hemolytic Anemia,Unspec
 ;;^UTILITY(U,$J,358.3,14585,1,4,0)
 ;;=4^D58.9
 ;;^UTILITY(U,$J,358.3,14585,2)
 ;;=^5002322
 ;;^UTILITY(U,$J,358.3,14586,0)
 ;;=C81.99^^61^740^88
 ;;^UTILITY(U,$J,358.3,14586,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14586,1,3,0)
 ;;=3^Hodgkin Lymphoma,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,14586,1,4,0)
 ;;=4^C81.99
 ;;^UTILITY(U,$J,358.3,14586,2)
 ;;=^5001460
 ;;^UTILITY(U,$J,358.3,14587,0)
 ;;=C81.90^^61^740^89
 ;;^UTILITY(U,$J,358.3,14587,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14587,1,3,0)
 ;;=3^Hodgkin Lymphoma,Unspec Site
 ;;^UTILITY(U,$J,358.3,14587,1,4,0)
 ;;=4^C81.90
 ;;^UTILITY(U,$J,358.3,14587,2)
 ;;=^5001451
 ;;^UTILITY(U,$J,358.3,14588,0)
 ;;=D89.2^^61^740^90
 ;;^UTILITY(U,$J,358.3,14588,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14588,1,3,0)
 ;;=3^Hypergammaglobulenemia,Unspec
 ;;^UTILITY(U,$J,358.3,14588,1,4,0)
 ;;=4^D89.2
 ;;^UTILITY(U,$J,358.3,14588,2)
 ;;=^5002455
 ;;^UTILITY(U,$J,358.3,14589,0)
 ;;=D05.12^^61^740^91
 ;;^UTILITY(U,$J,358.3,14589,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14589,1,3,0)
 ;;=3^Intraductal Carcinoma in Situ,Left Breast
